Cetera Trust Company N.A Invests $489,000 in Halozyme Therapeutics, Inc. $HALO

Cetera Trust Company N.A purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,250 shares of the biopharmaceutical company’s stock, valued at approximately $489,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Paradigm Capital Management Inc. NY acquired a new stake in Halozyme Therapeutics in the 2nd quarter worth about $783,000. Visionary Wealth Advisors acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $407,000. Whalen Wealth Management Inc. acquired a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $602,000. Infrastructure Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $673,000. Finally, Cibc World Market Inc. purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $309,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HALO has been the subject of several research reports. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Price Performance

HALO stock opened at $108.64 on Tuesday. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.10. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm has a market capitalization of $12.33 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The business has a 50 day simple moving average of $83.94 and a 200-day simple moving average of $73.96.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock valued at $5,226,496 in the last three months. 2.50% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.